This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "Guanabenz" – news · newspapers · books · scholar · JSTOR (September 2014) (Learn how and when to remove this template message)
Clinical data
Trade namesWytensin
AHFS/Drugs.comConsumer Drug Information
ATC code
  • none
Pharmacokinetic data
Protein binding90%
Elimination half-life6 hours
  • 2-(2,6-dichlorobenzylidene)hydrazinecarboximidamide
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.023.410 Edit this at Wikidata
Chemical and physical data
Molar mass231.08 g·mol−1
3D model (JSmol)
  • Clc1cccc(Cl)c1\C=N\N=C(/N)N
  • InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+ checkY

Guanabenz (pronounced GWAHN-a-benz, sold under the trade name Wytensin) is an alpha agonist that is selective to the alpha-2 adrenergic receptor. Guanabenz is used as an antihypertensive drug used in the treatment of high blood pressure (hypertension).[1][2]

The most common side effects during guanabenz therapy are dizziness, drowsiness, dry mouth, headache and weakness.[3]

Guanabenz can make one drowsy or less alert, therefore driving or operating dangerous machinery is not recommended.


Guanabenz also has some anti-inflammatory properties in different pathological situations, including multiple sclerosis.[4]

Guanabenz was found in one study to exert an inhibitory effect by decreasing the abundance of the enzyme CH25H, a cholesterol hydroxylase linked to antiviral immunity. Therefore, it is suggested that the drug and similar compounds could be used to treat type I interferon-dependent pathologies and that the CH25H enzyme could be a therapeutic target to control these diseases,[5] including amyotrophic lateral sclerosis.

See also


  1. ^ Walker BR, Hare LE, Deitch MW (1982). "Comparative antihypertensive effects of guanabenz and clonidine". The Journal of International Medical Research. 10 (1): 6–14. doi:10.1177/030006058201000102. PMID 7037502. S2CID 2139809.[permanent dead link]
  2. ^ Bonham AC, Trapani AJ, Portis LR, Brody MJ (December 1984). "Studies on the mechanism of the central antihypertensive effect of guanabenz and clonidine". Journal of Hypertension Supplement. 2 (3): S543–S546. PMID 6599714.[permanent dead link]
  3. ^ "Guanabenz | The Merck Index Online". Retrieved 2023-04-17.
  4. ^ Way SW, Podojil JR, Clayton BL, Zaremba A, Collins TL, Kunjamma RB, et al. (March 2015). "Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic". Nature Communications. 6: 6532. Bibcode:2015NatCo...6.6532W. doi:10.1038/ncomms7532. PMC 4360920. PMID 25766071.
  5. ^ Perego J, Mendes A, Bourbon C, Camosseto V, Combes A, Liu H, et al. (January 2018). "Guanabenz inhibits TLR9 signaling through a pathway that is independent of eIF2α dephosphorylation by the GADD34/PP1c complex". Science Signaling. 11 (514): eaam8104. doi:10.1126/scisignal.aam8104. hdl:10773/27856. PMID 29363586. S2CID 13680678.